Lercanidipine
| Evidence Level: N/A | Predicted Indications: 0 |
Table of Contents
- Lercanidipine
Lercanidipine: Known uses and market status in Australia
Summary
The TxGNN model produced no candidate indication for Lercanidipine with a score of 0.99 or higher, so there is currently no new predicted indication. The drug’s own recorded uses are listed below.
Quick overview
| Item | Content |
|---|---|
| New predicted indications | None (no model candidate scored 0.99 or higher) |
| Known uses recorded for this drug | 2 |
| Evidence level | Not applicable |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
Known uses recorded for this drug
Approved (supported by a licence or label)
| Indication | Source |
|---|---|
| none | none |
Related to an approved indication (same disease category)
| Indication | Approved category |
|---|---|
| none | none |
Relations recorded in the knowledge graph (no approval found)
| Indication |
|---|
| hypertension |
| hypertensive disorder |
Australia Market Information
| Licence | Product | Dosage form | Status |
|---|---|---|---|
| 13411W | Zircol 10 | Tablet containing lercanidipine hydrochl | Valid |
Safety Considerations
Please refer to the TGA-approved Product Information (PI) for safety information. No drug interaction records were found in the data compiled for this report. Calcium channel blockers carry a theoretical risk of worsening gas exchange and right heart function in hypoxic lung disease, which is relevant to the top predicted indication.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.